Tapentadol prolonged release for severe chronic pain: Results of a noninterventional study involving general practitioners and internists

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 27, Issue 3, 2013, Pages 225-234

  Schwittay, A ^a   Schumann, C ^a   Litzenburger, B C ^b   Schwenke, K ^b  

^a Special Pain Therapy and Palliative Medicine   (Germany)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

Daily clinical practice; Noninterventional study; Pain intensity; Pain management; Prolonged release; Severe chronic pain; Tapentadol

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; BUPRENORPHINE; DIPYRONE; FENTANYL; LAXATIVE; NALOXONE PLUS OXYCODONE; NALOXONE PLUS TILIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PALEXIA RETARD; TAPENTADOL; TILIDINE; TRAMADOL; UNCLASSIFIED DRUG;

ADL DISABILITY; ADULT; AGED; ANALGESIA; ARTICLE; BACKACHE; CANCER PAIN; CHRONIC PAIN; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONSTIPATION; CONTROLLED DRUG RELEASE; DIARRHEA; DISEASE SEVERITY; DRUG DOSAGE FORM; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENERAL PRACTITIONER; GERMANY; GOAL ATTAINMENT; HEADACHE; HIP PAIN; HUMAN; INTERNIST; KNEE PAIN; LIBIDO; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHIC PAIN; NUMERICAL RATING SCALE; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE; RESTLESSNESS; SLEEP DISORDER; SLEEP QUALITY; SOCIAL BEHAVIOR; SOMNOLENCE; VERTIGO; VISUAL DISORDER; VOMITING;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHRONIC PAIN; DELAYED-ACTION PREPARATIONS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PHENOLS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84883722817     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2013.816406     Document Type: Article

References (19)

1. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287-333.
2. Wolff R, Clar C, Lerch C, Kleijnen J. Epidemiologie von nicht tumorbedingten chronischen Schmerzen in Deutschland. Schmerz. 2011;25:26-44.
3. Muller-Schwefe G, Uberall MA. Schmerz und Lebensqualität. Gesundheitsökonomie & Qualitätsmanagement. 2011;16:S20-S22.
4. Manchikanti L, Ailinani H, Koyyalagunta D, et al. A systematic review of randomized trials of long-term opioid mangement for chronic non-cancer pain. Pain Physician. 2011;14:91-121.
5. Electronic Medicines Compendium. Palexia SR 50 mg prolonged-release tablets. Summary of product characteristics. Available at: http://www.medicines. org.uk/EMC/medicine/24389/SPC/Palexia+SR+50+mg+prolonged-release+tablets./ Accessed November 29, 2012.
6. Tzschentke TM, Christoph T, Schroder W, et al. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview]. Schmerz. 2011;25:19-25.
7. Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010;14:781-783.
8. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo-and active-controlled phase III study. Clin Drug Invest. 2010;30:489-505.
9. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, doubleblind, placebo-and active-controlled Phase III study. Expert Opin Pharmacother. 2010;11:1787-1804.
10. Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010;27:381-399.
11. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebocontrolled trial. Curr Med Res Opin. 2011;27:151-162.
12. Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10:416-427.
13. Merker M, Dinges G, Koch T, Kranke P, Morin AM. [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies]. Schmerz. 2012;26:16-26.
14. Steigerwald I, Muller M, Davies A, et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr Med Res Opin. 2012;28:911-936.
15. Grünenthal GmbH. Fachinformation Palexia® retard. Stand: August 2010.
16. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105-121. (Pubitemid 351147828)
17. Kiresuk TJ, Sherman RE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment Health J. 1968;4:443-453.
18. Fine PG, Portenoy RK. Ad hoc expert panel on evidence review and guidelines for opioid rotation: establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38:418-425.
19. Freye E. Opioide In der Medizin. 8. Aufage. Berlin and Heidelberg: Springer; 2009:144-145.